Company intelligence / Profile preview

54gene

Ownership: Private
Development stage: Preclinical

Overview

54gene was an African genomics company founded in January 2019 to address the underrepresentation of African genetic data in global research. It built one of Africa’s largest biobanks, partnered with Illumina to establish advanced sequencing facilities, and raised over $44 million across several funding rounds. The company pivoted during COVID to provide testing but faced financial challenges post-pandemic. It ceased operations by September 2023 after layoffs and leadership changes.

Therapeutic areas: Other
Modalities: Genomics-based research and servicesPrecision medicine (no evidence of small molecules or mAbs as primary modality)
Industry: Drug Discovery Services

Partnerships

Illumina (sequencing technology partnership)Collaborations with pharmaceutical companies for codevelopment/target discovery mentioned but not named specifically

Beyond the preview

Go deeper on 54gene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 54gene.

Explore the full profile